Minerva Neurosciences | NERV - 営業利益





営業利益 変化する 日付
Acadia Pharmaceuticals USD -4.62M 22.01M 2026-03
Adma Biologics USD 62.75M 11.74M 2025-12
ALKERMES USD -48.28M 37.33M 2026-03
Alterity Therapeutics Limited AUD -8.07M 302.4K 2025-12
AstraZeneca USD 7.11B 4.14B 2026-03
BioCryst Pharmaceuticals USD 260.38M 230.79M 2025-12
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Cipla INR 6.14B 3.63B 2026-03
Clal Biotechnology ILS -1.74M 7.46M 2022-12
Compugen USD 56.04M 63.93M 2025-12
CSL USD 2.64B 1.97B 2025-12
Eli Lilly USD 9.78B 792M 2026-03
Esperion Therapeutics USD 85.23M 95.19M 2025-12
GlaxoSmithKline GBP 2.29B 856M 2026-03
Grifols EUR 320.55M 91.01M 2025-12
Halozyme Therapeutics USD -61.77M 26.64M 2026-03
Ionis Pharmaceuticals USD -118M 97M 2026-03
J&J USD 6.62B 1.03B 2026-03
Merck USD -1.88B 8.12B 2026-03
Minerva Neurosciences USD -21.85M 17.48M 2024-12
Neurocrine Biosciences USD 214.6M 13.3M 2026-03
Novartis USD 4.24B 171M 2026-03
Novavax USD 20.94M 100.32M 2025-12
Pfizer USD 4.99B 340M 2026-03
Roche Holding CHF 9.56B 3.8B 2025-12
Sanofi EUR 1.94B 239M 2026-03
Takeda JPY -13.62B 182.44B 2026-03
Vanda Pharmaceuticals USD -40.66M 29.66M 2024-12